Navigation Links
DOR BioPharma Announces Publication Describing Results of Its,Multivalent Botulinum Toxin Vaccine BT-VACC

esults, performance, prospects and opportunities, including statements regarding the potential use of orBec® for the treatment of gastrointestinal GVHD and the prospects for regulatory filings for orBec®. Where possible, DOR has tried to identify these forward-looking statements by using words such as "anticipates," "believes," "intends," or similar expressions. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. DOR cannot assure you that it will be able to successfully develop or commercialize products based on its technology, including orBec®, particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that its technologies will prove to be safe and effective, that its cash expenditures will not exceed projected levels, that it will be able to obtain future financing or funds when needed, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the U.S. Government or other countries, that the U.S. Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
2. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
3. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
4. Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory Drugs
5. PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week
6. AVI BioPharma Reports Positive Pre-Clinical Influenza Data
7. Helix BioPharma Corp. Announces Positive Phase II Clinical Results with its Topical Interferon Alpha-2b
8. CeNeRx BioPharma Announces Positive Phase I Results in First Human Trial of Third Generation RIMA Antidepressant
9. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:7/10/2014)... Decision Resources Group finds that over half ... and Drug Administration,s (FDA) approval of Vifor Fresenius Medical ... approved by the FDA in November 2013 for the ... on dialysis. Other key findings from the ... : , Bundling: ...
(Date:1/15/2014)... and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the addition ... Analysis, Size, Share, Growth, Trends And Forecast, 2013 - ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Dental ... order to treat dental impairments, for tooth restoration and ...
(Date:1/15/2014)... (the "Company") (NASDAQ: CLSN ) today announced ... purchase an aggregate of approximately $15 million of the ... led by a dedicated health care fund. ... investors pursuant to which the Company agreed to sell ...
Breaking Medicine Technology:Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3
... PharmaTech (Cayman) Inc. (NYSE: WX ) ... general meeting of shareholders held in Hong Kong ... (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ) ... re-election of incumbent Class C directors Dr. Ge ...
... -Asia/ -- Winner Medical Group Inc. (Nasdaq: ... dressings, medical disposables and non-woven PurCotton® materials for the ... preliminary, unaudited financial results for its fiscal fourth quarter ... fourth quarter and year ended results are unaudited and ...
Cached Medicine Technology:WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2010 Annual General Meeting 2Winner Medical Announces Preliminary Fiscal Fourth Quarter 2010 Results 2Winner Medical Announces Preliminary Fiscal Fourth Quarter 2010 Results 3Winner Medical Announces Preliminary Fiscal Fourth Quarter 2010 Results 4Winner Medical Announces Preliminary Fiscal Fourth Quarter 2010 Results 5
(Date:7/11/2014)... Rochester, NY (PRWEB) July 11, 2014 ... Surgery ’s own, Dr. William Koenig, has topped a ... his peers, he has performed over 400 successful procedures ... , Dr. Koenig is well known across the country ... His exceptional safety record has long been the foundation ...
(Date:7/11/2014)... people with sex addiction, pornography affects the brain in ... addicts as they consume drugs, a new study finds. ... patients who have compulsive sexual behavior and healthy volunteers. ... Dr. Valerie Voon, of the University of Cambridge in ... research involved 19 men with sex addiction and a ...
(Date:7/11/2014)... July 11, 2014 (HealthDay News) -- U.S. health officials ... were exposed to live anthrax during a safety mishap ... Control and Prevention officials have announced a moratorium on ... high-level government labs. In a report issued Friday, ... to make sure a similar incident doesn,t occur again. ...
(Date:7/11/2014)... The report “Probiotics Market by Products (Functional Foods, ... Therapeutic, Preventive Health Care) & Ingredients (Lactobacilli, Bifidobacteria, ... ” defines and segments the global probiotics market ... value of probiotic products and ingredients. The report ... the global market with an analysis of trends, ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 According to ... & Application Market by Communication Technology (ZigBee, Z-Wave, Bluetooth, ... Electronics, Industrial, Automotive & Transportation, Agriculture) & Geography - ... value of Internet of Things market was worth $1029.5 ... Billion by 2020, at an estimated CAGR of 4.08% ...
Breaking Medicine News(10 mins):Health News:Rochester Surgeon Hits Milestone with Keller Funnel 2Health News:Brains of Sex Addicts May Be Wired Like Those of Drug Addicts, Study Finds 2Health News:CDC Issues Tough Report on Anthrax Scare 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 3Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 4Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 5Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 4
... of data across the Network will help physicians ... Wash., March 17 Virtua Health, a four-hospital ... process improvement, has selected Microsoft Amalga, the unified ... give physicians critical information and insight that help ...
... According to Deloitte SurveyWASHINGTON, March 17 As health care ... of consumers have expressed discontent with the status quo, rating ... A quarter of consumers have skipped care when they were ... done so because they simply could not afford it, were ...
... 17 FRIED LICE: "You don,t have to be such a ... manufacturing company, is set to introduce the latest in delousing technology. ... Disease Control "CDC" website. The guidelines are clear in stating: "to ... of 130 degrees." Lice Safe was able to adapt a ...
... China, March 17 /PRNewswire-Asia/ -- China Medicine ... "the Company"), a leading,developer and distributor of ... medicines (TCM), nutritional and dietary supplements, and,medical ... it will conduct,a conference call at 9:00 ...
... as they perform together , , TUESDAY, March 17 (HealthDay ... harmonize along with the music, according to new European ... of eight pairs of guitarists as they played a ... The study found that brain-wave similarities within and between ...
... costs and prevent preterm births, , , TUESDAY, March 17 (HealthDay ... company,s health insurance for a premature baby could cover the ... new report from the March of Dimes claims. , ... average $4,551, of which about $3,800 is covered by employer ...
Cached Medicine News:Health News:Virtua Health Selects Microsoft Amalga to Help Improve Patient Care 2Health News:Virtua Health Selects Microsoft Amalga to Help Improve Patient Care 3Health News:Virtua Health Selects Microsoft Amalga to Help Improve Patient Care 4Health News:Virtua Health Selects Microsoft Amalga to Help Improve Patient Care 5Health News:Need for Health Care Reform Escalates; One in Four Americans Skip Care When Sick or Injured 2Health News:Need for Health Care Reform Escalates; One in Four Americans Skip Care When Sick or Injured 3Health News:Need for Health Care Reform Escalates; One in Four Americans Skip Care When Sick or Injured 4Health News:Need for Health Care Reform Escalates; One in Four Americans Skip Care When Sick or Injured 5Health News:Need for Health Care Reform Escalates; One in Four Americans Skip Care When Sick or Injured 6Health News:Lice Safe Introduces Licen Tool 2Health News:China Medicine Announces Conference Call to Discuss Fourth and Fiscal Year 2008 Results 2Health News:Musicians' Brain Waves Are Also in Tune 2Health News:Tiniest Babies Carry Biggest Costs 2Health News:Tiniest Babies Carry Biggest Costs 3
Inquire...
The model 55D Rocking Shaker provides the same Reliable quality as the 55S, but double the value. The 55D gives you an additional platform with a height of 3.25 in....
Multi-Tier Shaker...
... incubate and shake up to 16 of AutoGen's ... time. This new system is most appropriate ... Proteinase K digestion. Now you can further ... samples with our AutoIncubator 96 and then placing ...
Medicine Products: